• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by I-MAB

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13D 1 tinvestment13d11302023.htm SCHEDULE 13D


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    (Rule 13d-101)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    § 240.13d-2(a)
    (Amendment No.)*
     
     
    I-MAB
    (Name of Issuer)
     
     Ordinary Shares
    (Title of Class of Securities)
     
     44975P1030
    (CUSIP Number)
     
     To Tony Chin
    T INVESTMENT LIMTED
    Flat B, 4th Floor, Haven Commercial Building
    6-8 Tsing Fung Street
    Hong Kong
    (852) 9013 6270

    With a copy to:
    Yang Wang, Esq.
    Stephen M. Leitzell, Esq.
    DECHERT LLP
    Circa Center
    2929 Arch Street
    Philadelphia, Pennsylvania 19104
    (215) 994-2621
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
     November 22, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     T INVESTMENT LIMITED
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS
     
     
     OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     BRITISH VIRGIN ISLANDS
     
     
     
     
    NUMBER OF UNITS BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     - 0 -
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     8,172,022 Ordinary Shares
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     - 0 -
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     8,172,022 Ordinary Shares
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     8,172,022 Ordinary Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN UNITS
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     9.89%
     
     
     
     
    14
    TYPE OF REPORTING PERSON
     
     
     IV
     
     
     
     
     


    CUSIP No. 44975P1030

    The following constitutes the Schedule 13D filed by the undersigned (the “Schedule 13D”).

    Item 1.  Security and Issuer.

    This statement relates to the Ordinary Shares, par value $0.0001 per share (the “Shares”), of I-MAB, an exempted Cayman Islands company (the “Issuer”). The address of the principal executive offices of the Issuer is Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, 201210, People’s Republic of China.

    Item 2.  Identity and Background.

    (a) This statement is filed by T Investment Limited, a British Virgin Islands business company (“T Invest”), with respect to the Shares directly and beneficially owned by it.  The foregoing entity is hereinafter sometimes referred to as the “Reporting Person”.
    (b) The address of the principal office of T Invest is Flat B, 4th Floor, Haven Commercial Building 6-8, Tsing Fung Street, Hong Kong.

    (c) T Invest is a private investment holding company.

    (d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e) The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    Item 3.  Source or Amount of Funds or Other Consideration.

    The Shares purchased by T Invest were purchase pursuant to a letter agreement with the Issuer. The aggregate purchase price of the 8,172,022 Shares beneficially owned by ART PL is approximately $11,849,431.90.
    Item 4.  Purpose of Transaction.

    The Reporting Person purchased the Shares based on the Reporting Person’s belief that the Shares represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Person, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares in private transactions or otherwise, on such terms and at such times as the Reporting Person may deem advisable.

    The Reporting Person does not have any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein. The Reporting Person intends to review its investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Person may in the future take such actions with respect to its investment in the Issuer as it deems appropriate including, without limitation, engaging in communications with management and the Board of Directors of the Issuer, engaging in discussions with unitholders of the Issuer or other third parties about the Issuer and the Reporting Person’s investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer’s financial and/or operational performance, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.


    Item 5.  Interest in Securities of the Issuer.

    The aggregate percentage of Shares reported owned by the Reporting Person named herein is based upon 191,911,402 Shares outstanding, as of March 31, 2023, which is the total number of Shares outstanding as reported in the Issuer’s Annual Report of Foreign Issuer on Form 20-F filed with the Securities and Exchange Commission on May 1, 2023.


    a.
    As of the close of business on November 22, 2023, T Invest beneficially owned 8,172,022 Shares.
    Percentage: Approximately 9.89%


    b.
    1. Sole power to vote or direct vote: 0
    2. Shared power to vote or direct vote: 8,172,022
    3. Sole power to dispose or direct the disposition: 0
    4. Shared power to dispose or direct the disposition: 8,172,022


    c.
    Except as disclosed herein, the Reporting Person has not effected any transactions during the past sixty (60) days in any securities of the Issuer.

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    None

    Item 7.  Material to Be Filed as Exhibits.

    None


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated:  November 23, 2023
     
      T INVESTMENT LIMITED
     
     
    By:
     /s/ To Tony Chin
       
    Name:   To Tony Chin
       
    Title:      Director
     
     

    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    SEC Filings

    View All

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/20/25 7:00:03 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/11/25 7:06:07 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by I-MAB

    424B5 - I-Mab (0001778016) (Filer)

    8/4/25 7:30:26 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Siebert Williams Shank initiated coverage on I-Mab with a new price target

    Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

    12/9/21 8:33:47 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on I-MAB with a new price target

    Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

    11/1/21 4:39:06 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

    HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

    9/1/21 6:14:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update

    Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion studyTopline data from planned dose expansion study of givastomig expected in Q1 2026Strengthened balance sheet with net proceeds of approximately $61.2 million from August 2025 underwritten offering; pro-forma cash balance of approximately $226.8 million as of June 30, 2025, after giving effect to the offering; expected to fund planned operating expenses and capital expenditures through the fourth quarter of 2028 ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (I

    8/20/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

    Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations. The Phase 1b study (NCT04900818) is evaluating the

    8/11/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Everest Medicines Expands Strategic Investment in I-MAB

    - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-T platform. - Complementary and synergistic clinical development and business development platforms, especially I-

    8/1/25 8:56:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

    Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

    1/6/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports Third Quarter 2024 Results

    Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

    11/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by I-MAB

    SC 13D - I-Mab (0001778016) (Subject)

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Financials

    Live finance-specific insights

    View All

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    10/31/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    8/28/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    8/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care